ViiV Healthcare Reports Dovato Matches Biktarvy Efficacy in Landmark HIV Study

ViiV Healthcare’s 2-drug regimen Dovato is as effective as 3-drug regimen Biktarvy in first-of-its-kind head-to-head study in treatment-naïve adults living with HIV ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Shionogi as a shareholder, announced data to be presented this…

Read MoreViiV Healthcare Reports Dovato Matches Biktarvy Efficacy in Landmark HIV Study
Thermo Fisher Scientific

Thermo Fisher Scientific Highlights End-to-End Lab and Diagnostic Innovations at ADLM 2026

Thermo Fisher Scientific Presents End-to-End Diagnostic and Lab Solutions Addressing Unmet Clinical Needs at ADLM 2026 Thermo Fisher Scientific, the world leader in serving science, will showcase its latest diagnostic innovations, recent regulatory milestones and expanded capabilities at the Association…

Read MoreThermo Fisher Scientific Highlights End-to-End Lab and Diagnostic Innovations at ADLM 2026
Precision BioSciences

Precision BioSciences Updates Senior Leadership Team to Support Clinical Development Progress

Precision BioSciences Announces Changes to Senior Leadership Team to Support Advancement of Programs Through Next Set of Clinical Milestones Precision BioSciences, Inc. a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies…

Read MorePrecision BioSciences Updates Senior Leadership Team to Support Clinical Development Progress
Merck Announces

Merck Announces Access Plans for Alimatravir, a Monthly Oral HIV PrEP Candidate in Phase 3 Development

Merck Announces Initial Access Plans for Alimatravir, an Investigational Once-Monthly Oral HIV Pre-Exposure Prophylaxis in Phase 3 Development Merck known as MSD outside of the United States and Canada, announced early components of a multi-faceted strategy to provide rapid, broad and sustainable…

Read MoreMerck Announces Access Plans for Alimatravir, a Monthly Oral HIV PrEP Candidate in Phase 3 Development
Enhertu®

Enhertu® and Pertuzumab Combination Recommended for EU Approval in HER2-Positive Metastatic Breast Cancer

Enhertu® Plus Pertuzumab Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with HER2 Positive Metastatic Breast Cancer Enhertu® (trastuzumab deruxtecan) in combination with pertuzumab has been recommended for approval in the European Union (EU) for the first-line…

Read MoreEnhertu® and Pertuzumab Combination Recommended for EU Approval in HER2-Positive Metastatic Breast Cancer
Vultr

Vultr and AMD Support Cambridge’s TESSERA AI Project to Advance Global Environmental Monitoring

Vultr and AMD Support the University of Cambridge’s TESSERA AI Project to Accelerate Global Environmental Monitoring Vultr, the world’s largest privately-held cloud infrastructure company, and AMD, a leader in high-performance and AI computing, have announced their support for the University of…

Read MoreVultr and AMD Support Cambridge’s TESSERA AI Project to Advance Global Environmental Monitoring
N-Zyme Biomedical

N-Zyme Biomedical Raises $4.6 Million Series A to Advance Clinical Development

N-Zyme Biomedical Closes US$4.6 Million Series A Financing to Advance Clinical Development N-Zyme Biomedical announced the successful closing of its Series A financing, raising approximately US$4.6 million to accelerate the advancement of its Phase 2 clinical programs and further the development of…

Read MoreN-Zyme Biomedical Raises $4.6 Million Series A to Advance Clinical Development
bioAffinity Technologies and Pictor®, Inc. Partner to Develop and Commercialize bioAffinity’s Diagnostics for Asthma and COPD

bioAffinity Technologies and Pictor Partner to Advance Commercialization of Asthma and COPD Diagnostics

bioAffinity Technologies and Pictor®, Inc. Partner to Develop and Commercialize bioAffinity’s Diagnostics for Asthma and COPD bioAffinity Technologies, Inc. a biotechnology company advancing early-stage cancer diagnostics and targeted therapeutics, today announced a collaboration with Pictor®, Inc., a targeted proteomic platform company, to…

Read MorebioAffinity Technologies and Pictor Partner to Advance Commercialization of Asthma and COPD Diagnostics
Wiley

Wiley Joins DOE’s Genesis Mission Consortium to Accelerate AI-Driven Scientific Innovation

Wiley Joins U.S. Department of Energy’s Genesis Mission Consortium to Advance AI-Powered Scientific Discovery Wiley announced its membership in the Genesis Mission Consortium, the public-private partnership supporting the U.S. Department of Energy’s (DOE) Genesis Mission, joining organizations including Nvidia, AWS,…

Read MoreWiley Joins DOE’s Genesis Mission Consortium to Accelerate AI-Driven Scientific Innovation
illumiSonics

illumiSonics and Sunnybrook Launch Laser Histology Trial for Mohs Surgery

illumiSonics and Sunnybrook Launch INOVAIT Focus Fund–Backed Clinical Trial Bringing Label-Free Laser Histology to Mohs Skin Cancer Surgery illumiSonics Inc., a medical technology company commercializing label-free tissue imaging, announced the launch of a prospective clinical validation study at Sunnybrook Health…

Read MoreillumiSonics and Sunnybrook Launch Laser Histology Trial for Mohs Surgery